Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Anti-Hypertensive Medication Use, Soluble Receptor For Glycation End Products And Risk Of Pancreatic Cancer In The Women's Health Initiative Study, Zhensheng Wang, Donna L. White, Ron Hoogeveen, Liang Chen, Eric A. Whitsel, Peter A. Richardson, Salim S. Virani, Jose M. Garcia, Hashem B. El-Serag, Li Jiao
Anti-Hypertensive Medication Use, Soluble Receptor For Glycation End Products And Risk Of Pancreatic Cancer In The Women's Health Initiative Study, Zhensheng Wang, Donna L. White, Ron Hoogeveen, Liang Chen, Eric A. Whitsel, Peter A. Richardson, Salim S. Virani, Jose M. Garcia, Hashem B. El-Serag, Li Jiao
Office of the Provost
Pancreatic cancer is the fourth leading cause of cancer death. Soluble receptor for glycation end products (sRAGE), which is modulated by anti-hypertensive (HT) medications, has been inversely associated with pancreatic cancer. However, the association between commonly used anti-HT medications and risk of pancreatic cancer is unknown. A total of 145,551 postmenopausal women from the Women Health Initiative (WHI) Study were included in analysis. Use of angiotensin converting enzyme inhibitors (ACEi), β-blockers, calcium channel blockers (CCBs) and diuretics was ascertained at baseline (1993⁻1998). Baseline sRAGE levels were measured among a subset of 2104 participants using an immunoassay. Multivariable Cox proportional hazard …